Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: Single centre early experience

Biomedical Imaging and Intervention Journal

Volumn 6, Issue 1, 2010, Pages

  Nawawi, Ouzreiah ^a   Hazman, M N ^a   Abdullah, B J J ^a   Vijayananthan, A ^a   Manikam, J ^a   Mahadeva, S ^a   Goh, K L ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Doxorubicin; Drug eluting beads; Embolisation; Hepatocellular carcinoma

Indexed keywords

DOXORUBICIN;

ADULT; AGED; ALOPECIA; ARTICLE; ARTIFICIAL EMBOLISM; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER RUPTURE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS PSEUDOCYST; PANCREATITIS; RADIOFREQUENCY ABLATION; SURGICAL TECHNIQUE; TREATMENT RESPONSE;

EID: 77749246470     PISSN: None     EISSN: 18235530     Source Type: Journal    
DOI: 10.2349/biij.6.1.e7     Document Type: Article

References (43)

1. Brown DB, Geschwind JF, Soulen MC et al. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 2006; 17(2 Pt 1):217-23.
2. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35(5):1164-71.
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37(2):429-42.
4. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359(9319):1734-9.
5. Lewis AL, Gonzalez MV, Lloyd AW et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006; 17(2 Pt 1):335-42.
6. Kettenbach J, Stadler A, Katzler IV et al. Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 2008; 31(3):468-76.
7. Hong K, Khwaja A, Liapi E et al. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006; 12(8):2563-7.
8. [Presented at AASLD, San Francisco, CA, 2005, November 11-15, abstract P485]. Varela M, Real MI, Brunet M et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads reduces the systemic availability of doxorubicin. A pharmacokinetic assessment.
9. Poon R. Treatment of Asian patients with hepatocellular carcinoma (HCC) using doxorubicin eluting beads embolization (PRECISION ASIA Study). [Presentation at CIRSE 2004, 25-29 September, Barcelona].
10. Varela M, Real MI, Burrel M et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46(3):474-81.
11. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19(3):329-38.
12. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35(3):421-30.
13. International Agency for Cancer Research. GLOBOCAN 2002 [Online]. Available at http://www-dep.iarc.fr. (Accessed 23 April 2007).
14. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19(3):271-85.
15. Lim GCC, Rampal S, Halimah , eds. 3rd Report of the National Cancer Registry: Incidence of Cancer in Peninsular Malaysia 2003-2005. Malaysia: National Cancer Registry, 2008.
16. Cheah PL, Looi LM, Nazarina AR et al. Histopathological landmarks of hepatocellular carcinoma in Malaysians. Malays J Pathol 2003; 25(1):37-43.
17. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362(9399):1907-17.
18. Benzoni E, Molaro R, Cedolini C et al. Liver resection for HCC: analysis of causes and risk factors linked to postoperative complications. Hepatogastroenterology 2007; 54(73):186-9.
19. Hong K, Georgiades CS, Geschwind JF. Technology insight: Image-guided therapies for hepatocellular carcinoma-intra-arterial and ablative techniques. Nat Clin Pract Oncol 2006; 3(6):315-24.
20. Malagari K, Chatzimichael K, Alexopoulou E et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008; 31(2):269-80.
21. Lammer J. Clinical experience with drug eluting bead (DC Bead) for chemoembolisation of unresectable hepatocellular carcinoma. [Data presentation at CIRSE 2005, Nice, France].
22. Pelletier G, Ducreux M, Gay F et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29(1):129-34.
23. Del Poggio P, Maddeo A, Zabbialini G et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads. J Hepatol 2007; 47(1):157-8; author reply 159.
24. Camma C, Schepis F, Orlando A et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224(1):47-54.
25. Liu CL, Ngan H, Lo CM et al. Ruptured hepatocellular carcinoma as a complication of transarterial oily chemoembolization. Br J Surg 1998; 85(4):512-4.
26. Battula N, Srinivasan P, Madanur M et al. Ruptured hepatocellular carcinoma following chemoembolization: a western experience. Hepatobiliary Pancreat Dis Int 2007; 6(1):49-51.
27. Lopez-Benitez R, Radeleff BA, Barragan-Campos HM et al. Acute pancreatitis after embolization of liver tumors: frequency and associated risk factors. Pancreatology 2007; 7(1):53-62.
28. Roullet MH, Denys A, Sauvanet A et al. [Acute clinical pancreatitis following selective transcatheter arterial chemoembolization of hepatocellular carcinoma]. Ann Chir 2002; 127(10):779-82.
29. Khan KN, Nakata K, Shima M et al. Pancreatic tissue damage by transcatheter arterial embolization for hepatoma. Dig Dis Sci 1993; 38(1):65-70.
30. Xia J, Ren Z, Ye S et al. Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol 2006; 59(3):407-12.
31. Leung TK, Lee CM, Chen HC. Anatomic and technical skill factor of gastroduodenal complication in post-transarterial embolization for hepatocellular carcinoma: a retrospective study of 280 cases. World J Gastroenterol 2005; 11(10):1554-7.
32. Chuang VP, Wallace S, Stroehlein J et al. Hepatic artery infusion chemotherapy: gastroduodenal complications. AJR Am J Roentgenol 1981; 137(2):347-50.
33. Granmayeh M, Wallace S, Schwarten D. Transcatheter occlusion of the gastroduodenal artery. Radiology 1979; 131(1):59-64.
34. Lewandowski RJ, Sato KT, Atassi B et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 2007; 30(4):571-92.
35. Song SY, Chung JW, Han JK et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 2001; 12(3):313-20.
36. Marelli L, Stigliano R, Triantos C et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30(1):6-25.
37. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 2001; 74(887):983-6.
38. Poon RT, Tso WK, Pang RW et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007; 5(9):1100-8.
39. Raoul JL, Guyader D, Bretagne JF et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26(5):1156-61.
40. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995; 332(19):1256-61.
41. Takayasu K, Muramatsu Y, Maeda T et al. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. AJR Am J Roentgenol 2001; 176(3):681-8.
42. Helmberger T, Dogan S, Straub G et al. Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. Digestion 2007; 75(2-3):104-12.
43. Veltri A, Moretto P, Doriguzzi A et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 2006; 16(3):661-9.